David Schilansky assumes CEO role, leveraging 25 years of experience in company formation, growth, and financing to propel Ariceum’s pipeline of innovative radiotherapeutics.

The Phase 1/2 SANTANA-225 study of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer (ES-SCLC) and Merkel Cell Carcinoma (MCC) is set to commence by the second half of 2025, with initial data anticipated in 2026.

BERLIN, Aug. 26, 2025 — Ariceum Therapeutics (Ariceum), a targeted radiotherapeutics firm committed to establishing new benchmarks in cancer treatment, announced today that David Schilansky, who previously served as Ariceum’s Chief Financial Officer, has been appointed as the Company’s new Chief Executive Officer. Mr. Schilansky takes over from Co-Founder and former CEO Manfred Rüdiger, PhD, who will continue to provide strategic counsel to the Company.

“I am excited to lead Ariceum into its next phase of expansion and am grateful to the Board for entrusting me with this responsibility. I wish to thank Manfred for his guidance during my onboarding, for passing the CEO leadership, and for building Ariceum into the pioneering company it is today,” stated David Schilansky, Chief Executive Officer of Ariceum Therapeutics. “At the forefront of radiopharmaceutical advancements, Ariceum is uniquely positioned to revolutionize treatment approaches for ES-SCLC and MCC with our primary candidate, 225Ac-SSO110, which holds the potential to be both a first-in-class and best-in-class therapy. We anticipate reporting initial safety outcomes in early 2026 and preliminary efficacy results in 2027, significant milestones that will mark a transformative period for our organization. As we begin this new chapter, our dedication remains fixed on advancing radioligand science and delivering substantial improvements in patient outcomes. By leveraging our team’s extensive expertise in the RLT sector and proven track record in scaling biotech enterprises, we are well-prepared to maximize the potential of 225Ac-SSO110 and establish Ariceum as a global leader in radiopharmaceuticals.”

The Company also unveiled leadership changes and a refreshed executive team designed to support Ariceum’s subsequent stage of development:

• Germo Gericke, a distinguished radiopharmaceutical leader, will continue in his role as Ariceum’s Chief Medical Officer.
• Susanna Mesa, an executive with global operations and strategy expertise in biotech, has been appointed Chief Operating Officer.
• Manuel Sturzbecher-Höhne, PhD, formerly the Head of CMC and Radiopharm Development, has been promoted to Chief Technology Officer.
• Greg Mullen, PhD, Ariceum’s former Chief Operations Officer, and Serge Sagodira, PhD, Ariceum’s former Chief Business Officer, are departing the Company to pursue other opportunities.

“Collectively, these accomplished leaders bring the vision, operational excellence, financial oversight, and innovative spirit necessary to drive Ariceum’s continued progress. David’s leadership and strategic insight will be instrumental in guiding Ariceum through its next growth phase,” commented Eduardo Bravo, Chairman of Ariceum Therapeutics. “We also wish to express our sincere gratitude to Manfred, who is stepping down for personal reasons as part of a planned transition, for his leadership, commitment, and strategic contributions, which have been vital in shaping Ariceum’s direction thus far. Furthermore, we extend our appreciation to Dr. Greg Mullen and Dr. Serge Sagodira for their invaluable contributions and unwavering dedication to the company’s mission. We wish them success in their future endeavors.”

About Ariceum Therapeutics
Ariceum Therapeutics is an oncology company in the clinical stage, committed to reshaping future care through targeted radiotherapeutics for patients battling aggressive and challenging-to-treat cancers. The company’s flagship program, 225Ac-SSO110, is a novel antagonist of the somatostatin type 2 receptor (SSTR2) with potential for best-in-class status. It is currently under investigation in the Phase 1/2 SANTANA-225 study as the first maintenance radiotherapy for extensive stage small cell lung cancer (ES-SCLC) and Merkel Cell Carcinoma (MCC) – two conditions with limited treatment options and poor prognoses. Ariceum is additionally advancing ATT001, a clinical product candidate comprising a novel radiolabeled I-123 PARP inhibitor engineered to deliver subcellular precision radiotherapy to aggressive solid tumors.

Headquartered in Berlin, Ariceum maintains operations across Germany, Switzerland, Australia, the United Kingdom, and the United States. The company receives backing from prominent global life sciences investors, including EQT Life Sciences, HealthCap, Pureos Bioventures, Andera Partners, and Earlybird Venture Capital.

For additional information, please contact:

Investors
Kevin Lui
Director, Investor Relations

Media
Genevieve Britton
Group Account Director, Public Relations